NEUROLOGY DEVICES MARKET ANALYSIS

Neurology Devices Market, By Device Type (CSF Management devices (CSF Shunt Devices and CSF Drainage Devices), Interventional Neurology Devices (Neuro Thromobectomy, Cerebral Balloon Angioplasty & Stents, Aneurysm Coiling, and Support Devices), Neuro-surgery Devices (Neuro-endoscopes, Sterotactic- Systems, Ultrasonic- Aspirators, and Aneurysm Clips), and Neuro-stimulation Devices (Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, and Gastric Nerve Stimulation)), By End user (Hospitals, Ambulatory Surgery Centers, and Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI3889
Pages :170
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Neurology Devices Market: Key Developments

On February, 2023, LivaNova PLC, a medical technology and innovation company, launched SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to provide Vagus Nerve Stimulation (VNS) Therapy for the treatment of drug-resistant epilepsy. The dual-pin header distinguishes this latest IPG from the original SenTiva, which is only available in a single-pin format. Now, with SenTiva DUO, patients considered “the pioneers of VNS Therapy” who were originally implanted with a dual-pin lead and IPG can receive the benefits of the latest VNS Therapy technology.

In January 2021, Boston Scientific Corporation, a medical device company, announced a limited market release of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems.

In June 2021, Medtronic, a medical device company, announced that it has received U.S. Food and Drug Administration (FDA) approval for Vanta, a high-performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years.

In January 2021, Boston Scientific Corporation, a medical device company, announced that the company have received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System.